Pharmacology of the Intraocular Pressure (IOP) Lowering Effect of Systemic Dexanabinol (HU-211), A Non-Psychotropic Cannabinoid
- 1 June 2000
- journal article
- Published by Mary Ann Liebert Inc in Journal of Ocular Pharmacology and Therapeutics
- Vol. 16 (3) , 217-230
- https://doi.org/10.1089/jop.2000.16.217
Abstract
The purpose of this study was to characterize the intraocular pressure (IOP) lowering activity and possible mechanism of action of the synthetic, non-psychotropic cannabinoid dexanabinol (HU-211) [(+)(3S,4S), 7-hydroxy-delta-6-tetrahydrocannabinol 1,1 dimethylheptyl], following intravenous (i.v.) administration in the rabbit. IOP (pneumatonometry), aqueous humor inflow rate (fluorophotometry), blood pressure, and heart rate (computerized physiograph system connected to central ear artery cannula) were measured in unanesthetized albino rabbits. Intravenous administration of HU-211 resulted in a dose-related reduction in IOP; a maximal IOP reduction of 5.0 +/- 0.2 mmHg was observed 4 hr after a 0.5 mg/kg dose. No significant changes in blood pressure or heart rate were observed during the first hr following this dose of HU-21 1. Pupil diameter did not change significantly during the 5 hr following the 0.5 mg/kg i.v. dose. No significant change in the rate of aqueous humor inflow occurred during the 6 hr after a 0.5 mg/kg dose of HU-211, thereby implicating outflow changes as the major source of IOP reduction. IOP reduction by HU-211 following pre-treatment with the alpha2 adrenergic antagonist, yohimbine (1 mg/kg, i.v.), was only 30% of that of HU-211 alone. IOP reduction following pretreatment with the alpha2 agonist, clonidine (0.5 mg/kg i.v.), was twice as large as that of HU-211 alone. Pretreatment with the beta-adrenergic antagonist, propranolol (0.5 mg/kg i.v.), resulted in a 50% reduction in the IOP-lowering effect of HU-211. In summary, HU-211, administered i.v., is an effective IOP-lowering agent, devoid of any significant side effects (blood pressure, heart rate or pupil diameter, all of which have been reported previously for cannabinoids). Involvement of the adrenergic system is indicated in mediating the IOP-lowering effects of HU-211 that appear to reflect a change in fluid outflow from the eye.Keywords
This publication has 32 references indexed in Scilit:
- HU-211, a nonpsychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in cultureNeuroReport, 1993
- A Comparison Between the Effect of Topical and Systemic Carbonic Anhydrase Inhibitors on Aqueous Humor SecretionExperimental Eye Research, 1993
- A novel probe for the cannabinoid receptorJournal of Medicinal Chemistry, 1992
- Stereochemical effects of 11-OH-Δ8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptorNeuropharmacology, 1990
- Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogsPharmacology Biochemistry and Behavior, 1989
- Central Nervous System and Peripheral Mechanisms in Ocular Hypotensive Effect of CannabinoidsArchives of Ophthalmology (1950), 1987
- Marijuana and the Eye - A ReviewJournal of Toxicology- Cutaneous and Ocular Toxicology, 1982
- The ocular effects of cannabinoidsGeneral Pharmacology: The Vascular System, 1980
- Cannabinoid action on the eye as mediated through the central nervous system and local adrenergic activityExperimental Eye Research, 1977
- Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous systemExperimental Eye Research, 1976